HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GENFLEET-B

24.700

-0.800-3.14%

Volume:988.60K

Turnover:24.63M

Market Cap:9.48B

PE:-4.07

High:25.280

Open:25.280

Low:24.660

Close:25.500

52wk High:52.900

52wk Low:19.600

Shares:384.00M

HK Float Shares:352.00M

Volume Ratio:1.03

T/O Rate:0.28%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-6.070

ROE:--

ROA:-12.49%

PB:4.47

PE(LYR):-4.07

PS:62.26

Loading ...

Overview Company News Filings

GenFleet Reports Stable Share Base in August; Confirms 19.86% Public Float Compliance

Bulletin Express

GENFLEET-B Allocates HK$1.08 Million to Buy Back Shares on September 2nd

Genfleet Therapeutics Files HKEX Next-Day Return Disclosing Share Buyback at HKD 27.6 Avg

The Consensus EPS Estimates For GenFleet Therapeutics (Shanghai) Inc. (HKG:2595) Just Fell Dramatically

Simply Wall St.

GenFleet Therapeutics Lung Cancer Drug Candidate Enters Phase 2 Trial

MT Newswires Live

HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off

GenFleet Pushes Lead KRAS G12D Candidate GFH375 into China Phase II First-Line NSCLC Trial, Testing Monotherapy and Combos with Cetuximab or Pemetrexed

Bulletin Express

Genfleet Therapeutics (Shanghai) - Gfh375 Enters Phase Ii Study for First-Line Kras G12d-Mutant Nsclc

THOMSON REUTERS

GenFleet Therapeutics (Shanghai) Reports Loss of Rmb220.17 Million for Six Months

GenFleet 1H26 Net Loss Narrows 68.5% to RMB220 Million as Other Income Surges, Cash Pile at RMB1.78 Billion

Bulletin Express

Genfleet Therapeutics (Shanghai) - Reports Loss of Rmb220.17 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS

Genfleet Therapeutics (Shanghai) - Reports Revenue of Rmb42.47 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS

GenFleet Interim Loss Narrows to RMB 220.17 Million in FY26 H1; Revenue Falls to RMB 42.47 Million

GENFLEET-B Advances Two First-in-Class Pancreatic Cancer Combination Therapies into Phase II Trials

GenFleet Starts Phase II Trial of KRAS G12D Inhibitor Gfh375 Combos in Pretreated Pancreatic Cancer Patients

GENFLEET-B: Wellington Management Group LLP Acquires Shares, Long Position Rises to 7.0%

Earning Preview: GENFLEET-B revenue outlook hinges on milestone timing as institutions remain cautious

GenFleet Therapeutics's Lung Cancer Drug Advances in Phase 3 Trial, First Patient Dosed

MT Newswires Live

GenFleet Rises Most in 4 Weeks on Progress of Gfh375 in Cancer Treatment

GenFleet Doses First Patient in China Phase III Trial of KRAS G12D Inhibitor Gfh375 for NSCLC

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/02595/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"GENFLEET-B","latestPrice":24.7,"timestamp":1789546126009,"preClose":25.5,"halted":0,"volume":988600,"delay":0,"changeRate":-0.03137254901960787,"floatShares":352000000,"shares":384000000,"eps":-6.07,"marketStatus":"Closed","change":-0.8,"latestTime":"09-16 16:08:46","open":25.28,"high":25.28,"low":24.66,"amount":24628832,"amplitude":0.024314,"askPrice":24.7,"askSize":2000,"bidPrice":24.68,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-3.946,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":5,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":25.5,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"volumeRatio":1.032502,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":352000000,"roa":"-12.49%","roe":"--","lyrEps":-6.07,"volumeRatio":1.032502,"shares":384000000,"dividePrice":0,"high":25.28,"amplitude":0.024314,"preClose":25.5,"low":24.66,"week52Low":19.6,"pbRate":"4.47","psRate":"62.26","week52High":52.9,"institutionHeld":0,"latestPrice":24.7,"committee":-0.428571,"eps":-6.07,"divideRate":0,"volume":988600,"delay":0,"ttmEps":-3.946,"open":25.28,"prevYearClose":23.78,"prevWeekClose":25.48,"prevMonthClose":30.8,"prevQuarterClose":29.44,"fiveDayClose":26.3,"twentyDayClose":29.8,"sixtyDayClose":26.66},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[{"date":"2026-08-21","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787275800000,"name":null,"time":"","dateTimestamp":1787241600000,"actualEps":null},{"date":"2026-03-24","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774315800000,"name":null,"time":"","dateTimestamp":1774281600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1788105600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2026-09-15","current":-6.259503,"percent":0.983333,"low":-19.62221,"twenty":-10.721918,"median":-9.519592,"eighty":-7.067323,"high":-5.69787,"avg":-9.381194,"sd":2.67468,"marketCap":9444349065},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-21","current":-10.329745,"twenty":-18.396816,"median":-10.725216,"eighty":-10.005136,"marketCap":10481375629},{"date":"2025-11-28","current":-10.423287,"twenty":-18.142029,"median":-10.678396,"eighty":-10.044836,"marketCap":10614707615},{"date":"2025-12-05","current":-10.100425,"twenty":-16.087956,"median":-10.631034,"eighty":-10.044836,"marketCap":10303599646},{"date":"2025-12-12","current":-10.212238,"twenty":-13.008301,"median":-10.584309,"eighty":-10.020393,"marketCap":10436931633},{"date":"2025-12-19","current":-9.790532,"twenty":-12.136764,"median":-10.450758,"eighty":-9.957409,"marketCap":10029528340},{"date":"2025-12-24","current":-8.945585,"twenty":-11.809112,"median":-10.416014,"eighty":-9.900509,"marketCap":9192499756},{"date":"2026-01-02","current":-8.020182,"twenty":-11.73453,"median":-10.320373,"eighty":-9.861601,"marketCap":8273990514},{"date":"2026-01-09","current":-11.588563,"twenty":-11.683046,"median":-10.309663,"eighty":-9.776189,"marketCap":11985064146},{"date":"2026-01-16","current":-11.693807,"twenty":-11.67863,"median":-10.369243,"eighty":-9.793132,"marketCap":12133210798},{"date":"2026-01-23","current":-10.361602,"twenty":-11.605818,"median":-10.329745,"eighty":-9.783265,"marketCap":10740632270},{"date":"2026-01-30","current":-10.919089,"twenty":-11.483053,"median":-10.385171,"eighty":-9.793132,"marketCap":11370255541},{"date":"2026-02-06","current":-11.146899,"twenty":-11.598147,"median":-10.450758,"eighty":-9.8258,"marketCap":11636919514},{"date":"2026-02-13","current":-10.659945,"twenty":-11.483053,"median":-10.58187,"eighty":-9.869606,"marketCap":11192479558},{"date":"2026-02-20","current":-10.145441,"twenty":-11.446311,"median":-10.573435,"eighty":-9.881527,"marketCap":10636929613},{"date":"2026-02-27","current":-9.574146,"twenty":-11.38719,"median":-10.509847,"eighty":-9.836956,"marketCap":10148045662},{"date":"2026-03-06","current":-8.841756,"twenty":-11.29428,"median":-10.416014,"eighty":-9.744297,"marketCap":9296202413},{"date":"2026-03-13","current":-10.316011,"twenty":-11.38719,"median":-10.450758,"eighty":-9.761464,"marketCap":10896186254},{"date":"2026-03-20","current":-10.186272,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"marketCap":10718410272},{"date":"2026-03-27","current":-5.945762,"twenty":-11.270982,"median":-10.329745,"eighty":-9.723416,"marketCap":12081359470},{"date":"2026-04-02","current":-6.621163,"twenty":-11.205287,"median":-10.312136,"eighty":-9.574146,"marketCap":13518381995},{"date":"2026-04-10","current":-7.067323,"twenty":-11.18954,"median":-10.310332,"eighty":-9.547859,"marketCap":14540593893},{"date":"2026-04-17","current":-8.194366,"twenty":-11.170082,"median":-10.271344,"eighty":-9.114302,"marketCap":16866496330},{"date":"2026-04-24","current":-11.736244,"twenty":-11.170082,"median":-10.248784,"eighty":-8.950161,"marketCap":18318333519},{"date":"2026-04-30","current":-10.233962,"twenty":-11.173069,"median":-10.230093,"eighty":-8.995356,"marketCap":15977616418},{"date":"2026-05-08","current":-9.881779,"twenty":-11.158327,"median":-10.186272,"eighty":-9.095725,"marketCap":15481325134},{"date":"2026-05-15","current":-8.422278,"twenty":-11.148553,"median":-10.161068,"eighty":-8.948635,"marketCap":13229496023},{"date":"2026-05-22","current":-7.916926,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"marketCap":12407282105},{"date":"2026-05-29","current":-8.035507,"twenty":-11.019944,"median":-10.082937,"eighty":-8.624127,"marketCap":12636909415},{"date":"2026-06-05","current":-6.909175,"twenty":-10.994143,"median":-10.039967,"eighty":-8.441141,"marketCap":10881371589},{"date":"2026-06-12","current":-6.584396,"twenty":-10.981505,"median":-9.989391,"eighty":-8.291507,"marketCap":10362858307},{"date":"2026-06-18","current":-6.718884,"twenty":-10.969649,"median":-9.941921,"eighty":-8.193596,"marketCap":10599892950},{"date":"2026-06-26","current":-5.732708,"twenty":-10.937065,"median":-9.927249,"eighty":-8.035507,"marketCap":8999909109},{"date":"2026-07-03","current":-7.180567,"twenty":-10.922684,"median":-9.900616,"eighty":-7.915515,"marketCap":11281367549},{"date":"2026-07-10","current":-9.054005,"twenty":-10.894174,"median":-9.893411,"eighty":-7.915515,"marketCap":14207263926},{"date":"2026-07-17","current":-8.396292,"twenty":-10.887172,"median":-9.884317,"eighty":-7.956496,"marketCap":13222088691},{"date":"2026-07-24","current":-8.187485,"twenty":-10.884642,"median":-9.862553,"eighty":-8.009423,"marketCap":12896166056},{"date":"2026-07-31","current":-6.510345,"twenty":-10.870773,"median":-9.833804,"eighty":-7.907869,"marketCap":10273970316},{"date":"2026-08-07","current":-7.003679,"twenty":-10.846908,"median":-9.792157,"eighty":-7.575355,"marketCap":11073962237},{"date":"2026-08-14","current":-7.214728,"twenty":-10.805358,"median":-9.754197,"eighty":-7.296139,"marketCap":11422106869},{"date":"2026-08-21","current":-7.917767,"twenty":-10.771121,"median":-9.6954,"eighty":-7.255608,"marketCap":12562836089},{"date":"2026-08-28","current":-7.346545,"twenty":-10.748709,"median":-9.635917,"eighty":-7.293508,"marketCap":11659141512},{"date":"2026-09-04","current":-6.41515,"twenty":-10.730984,"median":-9.570725,"eighty":-7.1768,"marketCap":10185082325},{"date":"2026-09-11","current":-5.935917,"twenty":-10.723237,"median":-9.522333,"eighty":-7.102704,"marketCap":9436941732},{"date":"2026-09-15","current":-5.941544,"twenty":-10.721918,"median":-9.519592,"eighty":-7.067323,"marketCap":9444349065}],"updateTime":1789555376156},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1143764036","title":"GenFleet Reports Stable Share Base in August; Confirms 19.86% Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1143764036","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143764036?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:21","pubTimestamp":1788348106,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. (GenFleet) disclosed in its Monthly Return for Equity Issuer that no changes occurred in its share capital during August 2026. At 31 August 2026, GenFleet’s...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186482960","title":"GENFLEET-B Allocates HK$1.08 Million to Buy Back Shares on September 2nd","url":"https://stock-news.laohu8.com/highlight/detail?id=1186482960","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186482960?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:08","pubTimestamp":1788347291,"startTime":"0","endTime":"0","summary":"On September 2nd, GENFLEET-B (02595) announced a share repurchase, investing approximately HK$1.0763 million to buy back 39,000 shares.The buyback was conducted at a total cost of HK$1.0763 million, reflecting the company's capital management strategy and its view on the current market valuation.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1161","159938","02595","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664214815","title":"Genfleet Therapeutics Files HKEX Next-Day Return Disclosing Share Buyback at HKD 27.6 Avg","url":"https://stock-news.laohu8.com/highlight/detail?id=2664214815","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664214815?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:07","pubTimestamp":1788347234,"startTime":"0","endTime":"0","summary":"Genfleet Therapeutics files HKEX next-day return disclosing share buyback at HKD 27.6 avgGenfleet Therapeutics repurchased 39,000 H shares on Sept. 2, holding them as treasury shares.Buyback price ran","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL5b07BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662257627","title":"The Consensus EPS Estimates For GenFleet Therapeutics (Shanghai) Inc. (HKG:2595) Just Fell Dramatically","url":"https://stock-news.laohu8.com/highlight/detail?id=2662257627","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662257627?lang=en_us&edition=fundamental","pubTime":"2026-08-27 06:11","pubTimestamp":1787782308,"startTime":"0","endTime":"0","summary":"One thing we could say about the analysts on GenFleet Therapeutics (Shanghai) Inc. ( HKG:2595 ) - they aren't...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2595/genfleet-therapeutics-shanghai-shares/news/the-consensus-eps-estimates-for-genfleet-therapeutics-shangh","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2595/genfleet-therapeutics-shanghai-shares/news/the-consensus-eps-estimates-for-genfleet-therapeutics-shangh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02595","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662798913","title":"GenFleet Therapeutics Lung Cancer Drug Candidate Enters Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662798913","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662798913?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:55","pubTimestamp":1787727342,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics  said GFH375 entered a phase II study for first-line treatment of patients with non-small cell lung cancer.The trial will be conducted in a number of clinical sites across China, with Guangdong Provincial People's Hospital as the leading site, according to a Wednesday Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02595","LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115078027","title":"HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1115078027","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115078027?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:17","pubTimestamp":1787707028,"startTime":"0","endTime":"0","summary":"Key corporate developments this week: GenFleet Therapeutics-B (02595) has initiated a Phase II study evaluating GFH375, an oral KRAS G12D inhibitor, as a first-line treatment for non-small cell lung...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","BK1574","LU0634319403.HKD","LU2476274308.USD","BK1526","LU0348827113.USD","BK1589","IE00B5MMRT66.SGD","BK4588","LU0417516571.SGD","LU0348767384.USD","BK1586","LU0561508036.HKD","BK1155","LU0540923850.HKD","LU0348735423.USD","LU1720050803.USD","IE00B543WZ88.USD","LU0417516902.SGD","LU2778985437.USD","LU2476274720.SGD","KCAI","00354","LU2488822045.USD","VXUS","LU1794554557.SGD","02595","09926","LU0348766576.USD","LU2399975544.HKD","BK4585","LU0348784397.USD","00660","LU0348783233.USD","BK1518","LU0417516738.SGD","LU0348825331.USD","IE00BPRC5H50.USD","KURE","BK1161","BK1237"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151749730","title":"GenFleet Pushes Lead KRAS G12D Candidate GFH375 into China Phase II First-Line NSCLC Trial, Testing Monotherapy and Combos with Cetuximab or Pemetrexed","url":"https://stock-news.laohu8.com/highlight/detail?id=1151749730","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151749730?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:06","pubTimestamp":1787702798,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (GenFleet; SEHK: 02595) has initiated a multicenter, open-label, randomized Phase II study to evaluate its oral KRAS G12D inhibitor GFH375 as a first-line treatment for advanced...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662276338","title":"Genfleet Therapeutics (Shanghai) - Gfh375 Enters Phase Ii Study for First-Line Kras G12d-Mutant Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2662276338","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662276338?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:00","pubTimestamp":1787702457,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44M0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661726566","title":"GenFleet Therapeutics (Shanghai) Reports Loss of Rmb220.17 Million for Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2661726566","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661726566?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:44","pubTimestamp":1787301897,"startTime":"0","endTime":"0","summary":"BRIEF-GenFleet Therapeutics  Reports Loss Of RMB220.17 Million For Six MonthsAug 21 -GenFleet Therapeutics  Inc2595.HK:REPORTS REVENUE OF RMB42.47 MILLION FOR SIX MONTHS ENDED JUNE 30, 2026REPORTS LOSS OF RMB220.17 MILLION FOR SIX MONTHS ENDED JUNE 30, 2026Further company coverage:2595.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161579224","title":"GenFleet 1H26 Net Loss Narrows 68.5% to RMB220 Million as Other Income Surges, Cash Pile at RMB1.78 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1161579224","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161579224?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:07","pubTimestamp":1787285225,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. (GenFleet) released unaudited interim results for the six months ended 30 June 2026, showing a significantly reduced net loss and strengthened liquidity despite...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GenFleet 1H26 Net Loss Narrows 68.5% to RMB220 Million as Other Income Surges, Cash Pile at RMB1.78 Billion","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661405251","title":"Genfleet Therapeutics (Shanghai) - Reports Loss of Rmb220.17 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661405251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661405251?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:02","pubTimestamp":1787284948,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1I7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661251403","title":"Genfleet Therapeutics (Shanghai) - Reports Revenue of Rmb42.47 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661251403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661251403?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:02","pubTimestamp":1787284948,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661514082","title":"GenFleet Interim Loss Narrows to RMB 220.17 Million in FY26 H1; Revenue Falls to RMB 42.47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661514082","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661514082?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:01","pubTimestamp":1787284885,"startTime":"0","endTime":"0","summary":"GenFleet interim loss narrows to RMB 220.17 million in FY26 H1; revenue falls to RMB 42.47 millionGenFleet Therapeutics posted a net loss of RMB 220.17 million for the six months ended June 30, 2026, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL2V87Ps:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193023804","title":"GENFLEET-B Advances Two First-in-Class Pancreatic Cancer Combination Therapies into Phase II Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1193023804","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193023804?lang=en_us&edition=fundamental","pubTime":"2026-08-20 08:16","pubTimestamp":1787184978,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) has announced the initiation of a three-arm, parallel-controlled Phase II clinical study evaluating GFH375, an oral KRAS G12D ON/OFF inhibitor. The trial will assess two novel...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09939","BK1574","02595","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660790224","title":"GenFleet Starts Phase II Trial of KRAS G12D Inhibitor Gfh375 Combos in Pretreated Pancreatic Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2660790224","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660790224?lang=en_us&edition=fundamental","pubTime":"2026-08-20 08:01","pubTimestamp":1787184103,"startTime":"0","endTime":"0","summary":"GenFleet starts Phase II trial of KRAS G12D inhibitor GFH375 combos in pretreated pancreatic cancer patientsGenFleet launched a three-arm Phase II trial in China for GFH375 in pretreated KRAS G12D-mut","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4NfWjt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103027770","title":"GENFLEET-B: Wellington Management Group LLP Acquires Shares, Long Position Rises to 7.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103027770","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103027770?lang=en_us&edition=fundamental","pubTime":"2026-08-17 17:12","pubTimestamp":1786957929,"startTime":"0","endTime":"0","summary":"On August 13, 2026, Wellington Management Group LLP bought 28,800 shares of GENFLEET-B (02595) (H shares) at an average of HKD 31.4819 per share, involving about HKD 906,679.Prior to the acquisition,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178800304","title":"Earning Preview: GENFLEET-B revenue outlook hinges on milestone timing as institutions remain cautious","url":"https://stock-news.laohu8.com/highlight/detail?id=1178800304","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178800304?lang=en_us&edition=fundamental","pubTime":"2026-08-14 09:34","pubTimestamp":1786671240,"startTime":"0","endTime":"0","summary":"Abstract GenFleet Therapeutics (Shanghai) Inc. will report quarterly results on August 21, 2026 post-Market; the update will likely center on margin resilience versus expanding R&D investment, with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: GENFLEET-B revenue outlook hinges on milestone timing as institutions remain cautious","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658437984","title":"GenFleet Therapeutics's Lung Cancer Drug Advances in Phase 3 Trial, First Patient Dosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2658437984","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658437984?lang=en_us&edition=fundamental","pubTime":"2026-08-10 17:31","pubTimestamp":1786354309,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics 's  GFH375 advanced into a registrational phase III study in China, according to a Monday Hong Kong bourse filing.The trial will be conducted across over 40 sites nationwide, with the first patient recently dosed at Nanjing Drum Tower Hospital.The trial will evaluate monotherapy efficacy and safety versus docetaxel in patients with KRAS G12D-mutant locally advanced, unresectable, or metastatic non-small cell lung cancer who have failed standard-of-care therapy.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02595","BK1161","BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658985346","title":"GenFleet Rises Most in 4 Weeks on Progress of Gfh375 in Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658985346","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658985346?lang=en_us&edition=fundamental","pubTime":"2026-08-10 15:21","pubTimestamp":1786346506,"startTime":"0","endTime":"0","summary":"BUZZ-GenFleet rises most in 4 weeks on progress of GFH375 in cancer treatment** Shares of GenFleet Therapeutics  Inc2595.HKrise 8.6% to HK$32.48, on course for their biggest one-day pct gain since July 15** Stock hits the highest point since July 28 in the fifth consecutive session of gain** China-based innovative drugs developer said its oral KRAS G12D inhibitorGFH375for cancer treatment has advanced into a multicenter, open-label, randomized controlled registrational phase III study in China for evaluating monotherapy efficacy and safety** YTD, stock up 34.4%, Hang Seng Biotech Index.HSBIOup 9%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N44705M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658056066","title":"GenFleet Doses First Patient in China Phase III Trial of KRAS G12D Inhibitor Gfh375 for NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658056066","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658056066?lang=en_us&edition=fundamental","pubTime":"2026-08-10 08:01","pubTimestamp":1786320110,"startTime":"0","endTime":"0","summary":"GenFleet doses first patient in China Phase III trial of KRAS G12D inhibitor GFH375 for NSCLCGenFleet started a registrational Phase III China trial of oral KRAS G12D inhibitor GFH375 in previously tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL50jB2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":116,"code":"91000000","status":"200"}]}}